Eaton Vance Management’s Apellis Pharmaceuticals APLS Stock Holding History

Eaton Vance Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.44M	Sell	50,324 -100	-0.2%	-$5.92K	0.01%	885
2022 Q2	$2.28M	Buy	+50,424	New	+$2.3M	﹤0.01%	1038
2022 Q1	–	Sell	-2,025	Closed	-$96K	–	1851
2021 Q4	$96K	Buy	2,025 +150	+8%	+$5.91K	﹤0.01%	1847
2021 Q3	$62K	Hold	1,875	–	–	﹤0.01%	1499
2021 Q2	$119K	Sell	1,875 -1,706	-48%	-$88K	﹤0.01%	1828
2021 Q1	$154K	Buy	+3,581	New	+$169K	﹤0.01%	1517

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Eaton Vance Management's APLS Position: Q3 2022 in Review

Eaton Vance Management reduced its Apellis Pharmaceuticals (APLS) stake by 0.2% in Q3 2022, selling an estimated $5.92K and leaving 50,324 shares worth $3.44M. The position accounts for 0.01% of the portfolio, ranked #885.

Eaton Vance Management first reported a position in APLS in Q1 2021 and has held it in 6 quarters since. 250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

Eaton Vance Management held 50,324 shares of Apellis Pharmaceuticals worth $3.44M as of Q3 2022.
Eaton Vance Management sold 100 Apellis Pharmaceuticals shares in Q3 2022, an estimated $5.92K.
Apellis Pharmaceuticals made up 0.01% of Eaton Vance Management's portfolio in Q3 2022, its #885 holding.
Eaton Vance Management first reported a position in Apellis Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.